左西孟旦治疗感染性休克合并心肌抑制的临床观察

熊芳; 刘超; 张可祥; 周岐龙; 卢花; 陈建国; 岳希; 赵建新; 潘鹏飞

doi:10.6039/j.issn.1001-0408.2024.20.13

您当前的位置：

首页 >

文章列表页 >

左西孟旦治疗感染性休克合并心肌抑制的临床观察

药物与临床 | 更新时间：2024-10-25

- 左西孟旦治疗感染性休克合并心肌抑制的临床观察
- Clinical observation of levosimendan in the treatment of septic shock combined with myocardial depression
- 中国药房 2024年35卷第20期页码：2517-2521
- 作者机构：
  
  1.重庆大学附属三峡医院重症医学科，重庆　404100
  2.锦州医科大学重庆大学附属三峡医院研究生联合培养基地，重庆　404100
- 作者简介：
  
  主治医师。研究方向：脓毒症的基础与临床研究。E-mail：171511884@qq.com
  主任医师，硕士生导师，博士。研究方向：脓毒症的基础与临床研究。E-mail：ppfswh@126.com
- 基金信息：
  
  重庆市自然科学基金面上项目(cstc2020jcyj-msxmX1069);重庆市科卫联合医学科研项目(2020FYYX133);重庆市卫生健康委中医药科研项目(2023WSJK143)
- DOI：10.6039/j.issn.1001-0408.2024.20.13
  中图分类号： R969.4;R542.2
- 纸质出版日期：2024-10-30，
  
  收稿日期：2024-03-25，
  
  修回日期：2024-09-09，
- 稿件说明：
移动端阅览
熊芳,刘超,张可祥等.左西孟旦治疗感染性休克合并心肌抑制的临床观察 ^Δ[J].中国药房,2024,35(20):2517-2521.

XIONG Fang,LIU Chao,ZHANG Kexiang,et al.Clinical observation of levosimendan in the treatment of septic shock combined with myocardial depression[J].ZHONGGUO YAOFANG,2024,35(20):2517-2521.
熊芳,刘超,张可祥等.左西孟旦治疗感染性休克合并心肌抑制的临床观察 ^Δ[J].中国药房,2024,35(20):2517-2521. DOI： 10.6039/j.issn.1001-0408.2024.20.13.

XIONG Fang,LIU Chao,ZHANG Kexiang,et al.Clinical observation of levosimendan in the treatment of septic shock combined with myocardial depression[J].ZHONGGUO YAOFANG,2024,35(20):2517-2521. DOI： 10.6039/j.issn.1001-0408.2024.20.13.

摘要

目的

探讨左西孟旦对感染性休克合并心肌抑制患者心脏功能、血流动力学和预后的影响，并评价其安全性。

方法

选择2021年4月－2023年8月入住重庆大学附属三峡医院重症医学科、经充分液体复苏、平均动脉压（MAP）≥65 mmHg且接受脉搏指示连续心输出量（PiCCO）监测的感染性休克合并心肌抑制患者，按随机数字表法分为多巴酚丁胺组和左西孟旦组，每组20例。两组患者均静脉泵入重酒石酸去甲肾上腺素注射液0.1～2.0 μg/（kg·min）。在此基础上，多巴酚丁胺组患者加用盐酸多巴酚丁胺注射液5～10 μg/（kg·min），连续静脉泵入3～7 d；左西孟旦组患者加用左西孟旦注射液0.1～0.2 μg/（kg·min），连续静脉泵入24 h。比较两组患者治疗前及治疗后24、72 h的心率（HR）和血流动力学指标[收缩压、舒张压、MAP、中心静脉压（CVP）]、PiCCO监测指标[心功能指数（CFI）、心指数（CI）、每搏量指数（SVI）、血管外肺水指数、全心舒张末期容积指数、肺血管通透性指数（PVPI）、全心射血分数（GEF）、系统血管阻力指数、左心室收缩力指数]和预后指标[用药后3 d内死亡情况、机械通气时间、住重症监护病房（ICU）时间、28 d病死率]，记录两组患者的不良反应发生情况。

结果

与同组治疗前比较，多巴酚丁胺组患者治疗后24 h的CFI、CI、GEF和治疗后72 h的CI、GEF以及左西孟旦组患者治疗后24 h的SVI和治疗后72 h的SVI、GEF均显著升高，多巴酚丁胺组患者治疗后72 h的PVPI显著降低（

＜0.05）；与同期多巴酚丁胺组比较，左西孟旦组患者治疗后24 h的HR显著降低，CVP显著升高（

＜0.05）。给药后3 d内，两组均无患者死亡；其机械通气时间、住ICU时间、28 d病死率和不良反应发生率比较差异均无统计学意义（

＞0.05）。

结论

对于经充分液体复苏、MAP≥65 mmHg且接受PiCCO监测的感染性休克合并心肌抑制患者，左西孟旦在改善心脏功能和血流动力学方面的作用与多巴酚丁胺相当，且不会影响患者预后，也不会增加低血压等不良反应的发生风险。

Abstract

OBJECTIVE

To explore the effects of levosimendan on cardiac function， hemodynamics and prognosis of patients with septic shock complicated with myocardial depression， and evaluate the safety of levosimendan.

METHODS

Patients with septic shock complicated with myocardial depression who were admitted to the Department of Critical Care Medicine of Chongqing University Three Gorges Hospital from April 2021 to August 2023， underwent adequate fluid resuscitation， had a mean arterial pressure （MAP） ≥65 mmHg， and received pulse indicator continuous cardiac output （PiCCO） monitoring were enrolled. The patients were randomly divided into dobutamine group and levosimendan group according to a random number table， with 20 patients in each group. Both groups received intravenous infusion of Norepinephrine bitartrate injection at a dose of 0.1-2.0 μg/（kg·min）. On this basis， the dobutamine group additionally received intravenous infusion of Dobutamine hydrochloride injection at a dose of 5-10 μg/（kg·min） for 3 to 7 days， while the levosimendan group additionally received intravenous infusion of Levosimendan injection at a dose of 0.1-0.2 μg/（kg·min） for 24 hours. Heart rate （HR） and hemodynamic parameters [systolic blood pressure， diastolic blood pressure， MAP， central venous pressure （CVP）]， PiCCO monitoring parameters [cardiac function index （CFI）， cardiac index （CI）， stroke volume index （SVI）， extravascular lung water index， global end-diastolic volume index， pulmonary vascular permeability index （PVPI）， global ejection fraction （GEF）， systemic vascular resistance index， left ventricular contractility index]， and prognosis indicators [death within 3 days after administration， mechanical ventilation time， intensive care unit （ICU） stay time， 28-day mortality rate] were compared between the two groups before treatment and at 24 and 72 hours after treatment. Adverse reactions were recorded for both groups.

RESULTS

Compared with before treatment in the same group， CFI， CI and GEF at 24 hours after treatment， CI and GEF at 72 hours after treatment in the dobutamine group， as well as SVI at 24 hours after treatment and SVI and GEF at 72 hours after treatment in the levosimendan group were significantl

y increased； PVPI at 72 hours after treatment in the dobutamine group was significantly decreased （

＜0.05）. Compared with the dobutamine group during the same period， patients in the levosimendan group had significantly lower HR and significantly higher CVP at 24 hours after treatment （

＜0.05）. Within 3 days after administration， there were no deaths in either group； there were no statistically significant differences in mechanical ventilation time， ICU stay time， 28-day mortality rate， or the incidence of adverse reactions between the two groups （

＞0.05）.

CONCLUSIONS

For patients with septic shock complicated with myocardial depression who have undergone adequate fluid resuscitation and have a MAP of ≥65 mmHg， levosimendan is comparable to dobutamine in improving cardiac function and hemodynamic parameters， without affecting patients’ prognosis or increasing the risk of adverse reactions such as hypotension.

关键词

左西孟旦感染性休克心肌抑制多巴酚丁胺脉搏指示连续心输出量监测

Keywords

septic shockmyocardial depressiondobutaminepulse indicator continuous cardiac output monitoring

references

田文龙，程红颖，董士民. 左西孟旦治疗严重脓毒症及脓毒症休克的临床疗效的Meta分析[J]. 临床荟萃，2018，33（7）：562-567.

TIAN W L，CHENG H Y，DONG S M. Meta analysis of levosimendan in treatment of severe sepsis and septic shock[J]. Clin Focus，2018，33（7）：562-567.

LIU D H，NING Y L，LEI Y Y，et al. Levosimendan versus dobutamine for sepsis-induced cardiac dysfunction：a systematic review and meta-analysis[J]. Sci Rep，2021，11（1）：20333.

EVANS L，RHODES A，ALHAZZANI W，et al. Survi-ving sepsis campaign：international guidelines for management of sepsis and septic shock 2021[J]. Intensive Care Med，2021，47（11）：1181-1247.

SHEN X D，ZHANG H S，ZHANG R，et al. Progress in the clinical assessment and treatment of myocardial depression in critically ill patient with sepsis[J]. J Inflamm Res，2022，15：5483-5490.

SANGALLI F，BELLANI G，AFFRONTI A，et al. Levosimendan to facilitate weaning from cardiorespiratory support in critically ill patients：current evidence and future directions[J]. Minerva Anestesiol，2020，86（6）：645-651.

FARMAKIS D，ALVAREZ J，BEN GAL T，et al. Levosimendan beyond inotropy and acute heart failure：evidence of pleiotropic effects on the heart and other organs：an expert panel position paper[J]. Int J Cardiol，2016，222：303-312.

PiCCO监测技术操作管理共识专家组. PiCCO监测技术操作管理专家共识[J]. 中华急诊医学杂志，2023，32（6）：724-735.

Expert Group of Expert Consensus on Operation Management of PiCCO Monitoring Technology. Expert consensus on operation management of PiCCO monitoring techno-logy[J]. Chin J Emerg Med，2023，32（6）：724-735.

SINGER M，DEUTSCHMAN C S，SEYMOUR C W，et al. The third international consensus definitions for sepsis and septic shock：sepsis-3[J]. JAMA，2016，315（8）：801-810.

BOISSIER F，AISSAOUI N. Septic cardiomyopathy：diagnosis and management[J]. J Intensive Med，2022，2（1）：8-16.

HERPAIN A，BOUCHEZ S，GIRARDIS M，et al. Use of levosimendan in intensive care unit settings：an opinion paper[J]. J Cardiovasc Pharmacol，2019，73（1）：3-14.

RHODES A，EVANS L E，ALHAZZANI W，et al. Survi-ving sepsis campaign：international guidelines for management of sepsis and septic shock：2016[J]. Intensive Care Med，2017，43（3）：304-377.

刘红娟，耿静，何志红，等. 左西孟旦治疗脓毒症心肌抑制的疗效及对心功能的影响[J]. 临床内科杂志，2020，37（6）：447-448.

LIU H J，GENG J，HE Z H，et al. Effect of levosimendan on myocardial inhibition and cardiac function in sepsis[J]. J Clin Intern Med，2020，37（6）：447-448.

PAN J，YANG Y M，ZHU J Y，et al. Multiorgan drug action of levosimendan in critical illnesses[J]. Biomed Res Int，2019，2019：9731467.

OSPINA-TASCÓN G A，CALDERÓN-TAPIA L E. Inodilators in septic shock：should these be used?[J]. Ann Transl Med，2020，8（12）：796.

YANG F，ZHAO L N，SUN Y，et al. Levosimendan as a new force in the treatment of sepsis-induced cardiomyopathy：mechanism and clinical application[J]. J Int Med Res，2019，47（5）：1817-1828.

ZANGRILLO A，PUTZU A，MONACO F，et al. Levosimendan reduces mortality in patients with severe sepsis and septic shock：a meta-analysis of randomized trials[J]. J Crit Care，2015，30（5）：908-913.

GORDON A C，PERKINS G D，SINGER M，et al. Levosimendan for the prevention of acute organ dysfunction in sepsis[J]. N Engl J Med，2016，375（17）：1638-1648.

GUAN Q C，ZHANG C，LI B B，et al. Meta-analysis of the efficacy of levosimendan in the treatment of severe sepsis complicated with septic cardiomyopathy[J]. Heart Surg Forum，2023，26（5）：E609-E620.

PONIKOWSKI P，VOORS A A，ANKER S D，et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure：the task force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology （ESC） developed with the special contribution of the Heart Failure Association（HFA）of the ESC[J]. Eur Heart J，2016，37（27）：2129-2200.

TAN R M，GUO H，YANG Z N，et al. Efficacy and safety of levosimendan in patients with sepsis：a systematic review and network meta-analysis[J]. Front Pharmacol，2024，15：1358735.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

暂无数据